|
| | PROSTAGLANDIN J2 Basic information |
| Product Name: | PROSTAGLANDIN J2 | | Synonyms: | 11-OXO-15S-HYDROXY-PROSTA-5Z,9,13E-TRIEN-1-OIC ACID;(5Z,13E,15S)-15-HYDROXY-11-OXOPROSTA-5,9,13-TRIEN-1-OIC ACID;PROSTAGLANDIN J2;PGJ2;9-deoxy-delta-9-prostaglandind2;PROSTAGLANDIN J2, 5MG/ML IN METHYL ACETA;(Z)-7-[(1S,5R)-5-[(E,3S)-3-hydroxyoct-1-enyl]-4-oxo-1-cyclopent-2-enyl]hept-5-enoic acid;(5Z,13E,15S)-15-Hydroxy-11-oxoprosta-5,9,13-triene-1-oic acid | | CAS: | 60203-57-8 | | MF: | C20H30O4 | | MW: | 334.45 | | EINECS: | 201-185-2 | | Product Categories: | | | Mol File: | 60203-57-8.mol |  |
| | PROSTAGLANDIN J2 Chemical Properties |
| Boiling point | 521.7±50.0 °C(Predicted) | | density | 1.103±0.06 g/cm3(Predicted) | | storage temp. | −20°C | | solubility | DMF: >100 mg/ml (from PGD2); DMSO: >50 mg/ml (from PGD2); Ethanol: >75 mg/ml (from PGD2); PBS pH 7.2: >2.7 mg/ml (from 15-deoxy-.DEL | | pka | 4.75±0.10(Predicted) |
| | PROSTAGLANDIN J2 Usage And Synthesis |
| Description | Prostaglandin J2 (PGJ2) is formed from PGD2 by the elimination of the C-9 hydroxyl group, a process which is accelerated by the presence of albumin. PGJ2 inhibits platelet aggregation with an IC50 of about 5-10 nM. PGJ2 has antimitotic and antiproliferative effects on a variety of cultured normal cells and tumor cell lines. However, this activity has been attributed to further metabolites of PGJ2 and not the parent compound itself. | | Uses | PGJ2 (Prostaglandin J2) is a Prostaglandin D2 metabolite that has shown potent anti-neoplastic and antiviral activity. | | Definition | ChEBI: A member of the class of prostaglandins J that consists of prosta-5,9,13-trien-1-oic acid substituted by an oxo group at position 11 and a hydroxy group at position 15 (the 5Z,13E,15S stereoisomer). |
| | PROSTAGLANDIN J2 Preparation Products And Raw materials |
|
